SubsidieMeestersPioneering diagnostics in dermatology and cancer
Dermagnostix aims to enhance dermatological diagnostics with a rapid, automated platform for precise molecular testing, reducing misdiagnoses and improving patient care.
Projectdetails
Introduction
At Dermagnostix, we envision the next level for molecular diagnostics in human skin to improve patients’ lives and clinical practice in dermatology.
Background
Skin diseases are the 4th most relevant human illnesses according to loss of quality of life.
Challenges in Conventional Diagnostics
Conventional diagnostics in dermatology based on clinical view and histopathology are imprecise and subjective, resulting in:
- Up to 50% of misdiagnosed cases
- Insufficient or harmful therapies
Our Solution
At Dermagnostix, we have developed a comprehensive technological platform for fast and objective molecular diagnostics in dermatology to:
- Reduce health care costs
- Improve patient treatment
Technological Platform
Our fully automated platform delivers results within 90 minutes, and testing can be run everywhere and at any time.
Key Features
Our easy-to-handle diagnostic device brings objective and precise skin diagnostics to reality, allowing:
- Simultaneous detection of up to 40 different molecular targets within one single test.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.499.000 |
| Totale projectbegroting | € 5.169.182 |
Tijdlijn
| Startdatum | 1-10-2022 |
| Einddatum | 30-9-2024 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- DERMAGNOSTIX GMBHpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
A new cardioprotective drug for acute treatment of myocardial infarctionResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Clear, scalable and scientific framework to measure terrestrial biodiversity3Bee leverages IoT, wildlife monitoring, and satellite data to measure and regenerate biodiversity, generating certified Biodiversity Credits for corporations to enhance ESG reporting and brand value. | EIC Accelerator | € 2.252.714 | 2024 | Details |
Novel and Scalable microbial products for REgenerative agricultureN-Spire aims to revolutionize agriculture by creating a sustainable bioactive fertilizer through innovative manufacturing techniques, enhancing soil health and reducing chemical dependency. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Quantum-based Randomness Processing Units (RPUs) for High-Performance Computation and Data SecurityQuside's Randomness Processing Unit (RPU) accelerates stochastic HPC and PQ cryptography by optimizing random workloads, enhancing efficiency and performance across various sectors. | EIC Accelerator | € 2.499.999 | 2024 | Details |
A new cardioprotective drug for acute treatment of myocardial infarction
ResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies.
Clear, scalable and scientific framework to measure terrestrial biodiversity
3Bee leverages IoT, wildlife monitoring, and satellite data to measure and regenerate biodiversity, generating certified Biodiversity Credits for corporations to enhance ESG reporting and brand value.
Novel and Scalable microbial products for REgenerative agriculture
N-Spire aims to revolutionize agriculture by creating a sustainable bioactive fertilizer through innovative manufacturing techniques, enhancing soil health and reducing chemical dependency.
Quantum-based Randomness Processing Units (RPUs) for High-Performance Computation and Data Security
Quside's Randomness Processing Unit (RPU) accelerates stochastic HPC and PQ cryptography by optimizing random workloads, enhancing efficiency and performance across various sectors.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Leveraging CRISPR-Cas for fast and accurate point-of-care diagnosticsScope Biosciences aims to validate its patented CRISPR-Cas diagnostic technology, scopeDx, for rapid, accurate, and adaptable point-of-care diagnostics in healthcare. | EIC Transition | € 2.498.125 | 2024 | Details |
Digital Skintyping Platform based on dermoscopy & AII-Parse ontwikkelt een digitaal platform dat AI gebruikt om huidtype te analyseren via dermatoscoopbeelden, met als doel het risico op huidkanker te verminderen en monitoring te verbeteren. | MIT Haalbaarheid | € 18.888 | 2022 | Details |
Uitbreiding methylatie platformsMLA Dx ontwikkelt een prognostische test voor vroeg stadium melanomen op basis van de LY75 biomarker om de diagnose en behandeling te verbeteren en sterfte te verminderen. | MIT Haalbaarheid | € 20.000 | 2021 | Details |
Uitbreiding methylatie platformsMLA Dx ontwikkelt een prognostische methode voor vroeg stadium melanomen via LY75 methylatie, ter verbetering van diagnose en behandeling. | MIT Haalbaarheid | € 20.000 | 2021 | Details |
Leveraging CRISPR-Cas for fast and accurate point-of-care diagnostics
Scope Biosciences aims to validate its patented CRISPR-Cas diagnostic technology, scopeDx, for rapid, accurate, and adaptable point-of-care diagnostics in healthcare.
Digital Skintyping Platform based on dermoscopy & AI
I-Parse ontwikkelt een digitaal platform dat AI gebruikt om huidtype te analyseren via dermatoscoopbeelden, met als doel het risico op huidkanker te verminderen en monitoring te verbeteren.
Uitbreiding methylatie platforms
MLA Dx ontwikkelt een prognostische test voor vroeg stadium melanomen op basis van de LY75 biomarker om de diagnose en behandeling te verbeteren en sterfte te verminderen.
Uitbreiding methylatie platforms
MLA Dx ontwikkelt een prognostische methode voor vroeg stadium melanomen via LY75 methylatie, ter verbetering van diagnose en behandeling.